Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Hybrid closed-loop systems for the treatment of type 1 diabetes : a collaborative, expert group position statement for clinical use in Central and Eastern Europe
ID
Janež, Andrej
(
Avtor
),
ID
Battelino, Tadej
(
Avtor
),
ID
Klupa, Tomasz Klupa
(
Avtor
),
ID
Kocsis, Győző
(
Avtor
),
ID
Kuricová, Miriam
(
Avtor
),
ID
Lalić, Nebojsa M.
(
Avtor
),
ID
Pantea Stoian, Anca
(
Avtor
),
ID
Prázný, Martin
(
Avtor
),
ID
Rahelić, Dario
(
Avtor
),
ID
Šoupal, Jan
(
Avtor
),
ID
Tankova, Tsvetalina
(
Avtor
),
ID
Zelinska, Nataliya
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(929,80 KB)
MD5: 0DC34438268DFD12322253CAEA2F139B
URL - Izvorni URL, za dostop obiščite
https://link.springer.com/article/10.1007%2Fs13300-021-01160-5
Galerija slik
Izvleček
In both pediatric and adult populations with type 1 diabetes (T1D), technologies such as continuous subcutaneous insulin infusion (CSII), continuous glucose monitoring (CGM), or sensor-augmented pumps (SAP) can consistently improve glycemic control [measured as glycated hemoglobin (HbA1c) and time in range (TIR)] while reducing the risk of hypoglycemia. Use of technologies can thereby improve quality of life and reduce the burden of diabetes management compared with self-injection of multiple daily insulin doses (MDI). Novel hybrid closed-loop (HCL) systems represent the latest treatment modality for T1D, combining modern glucose sensors and insulin pumps with a linked control algorithm to offer automated insulin delivery in response to blood glucose levels and trends. HCL systems have been associated with increased TIR, improved HbA1c, and fewer hypoglycemic events compared with CSII, SAP, and MDI, thereby potentially improving quality of life for people with diabetes (PwD) while reducing the costs of treating short- and long-term diabetes-related complications. However, many barriers to their use and regional inequalities remain in Central and Eastern Europe (CEE). Published data suggest that access to diabetes technologies is hindered by lack of funding, underdeveloped health technology assessment (HTA) bodies and guidelines, unfamiliarity with novel therapies, and inadequacies in healthcare system capacities. To optimize the use of diabetes technologies in CEE, an international meeting comprising experts in the field of diabetes was held to map the current regional access, to present the current national reimbursement guidelines, and to recommend solutions to overcome uptake barriers. Recommendations included regional and national development of HTA bodies, efficient allocation of resources, and structured education programs for healthcare professionals and PwD. The responsibility of the healthcare community to ensure that all individuals with T1D gain access to modern technologies in a timely and economically responsible manner, thereby improving health outcomes, was emphasized, particularly for interventions that are cost-effective.
Jezik:
Angleški jezik
Ključne besede:
hybrid closed loop
,
advanced hybrid closed-loop
,
type 1 diabetes
,
Central and Eastern Europe
,
position statement
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
MF - Medicinska fakulteta
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2021
Št. strani:
Str. 3107-3135
Številčenje:
Vol. 12, iss. 12
PID:
20.500.12556/RUL-134828
UDK:
616.379
ISSN pri članku:
1869-6961
DOI:
10.1007/s13300-021-01160-5
COBISS.SI-ID:
80055043
Datum objave v RUL:
03.02.2022
Število ogledov:
1269
Število prenosov:
126
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Diabetes therapy
Skrajšan naslov:
Diabetes ther.
Založnik:
Springer Nature
ISSN:
1869-6961
COBISS.SI-ID:
520452889
Licence
Licenca:
CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by-nc/4.0/deed.sl
Opis:
Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.
Začetek licenciranja:
25.10.2021
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
hibridna zaprta zanka
,
sladkorna bolezen tipa 1
,
srednja in vzhodna Evropa
Projekti
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
Medtronic International Trading Sarl
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj